MA-EXAGRID
18.8.2020 14:02:10 CEST | Business Wire | Press release
ExaGrid ® today announced that CloudComputing.pt , Portugal’s premier enterprise cloud computing strategy provider, led Lusitania Seguros to install ExaGrid’s Tiered Backup Storage solution, which bolstered the insurance company’s data protection by increasing the capacity and variety of its data backups.
Lusitania emerged in the insurance market in 1986 as the first Insurance Company with 100% Portuguese capital. Since then, and over more than 30 years, it has always designed itself as a company with an eye on the future. A reliable partner in all situations, focusing on creating value for the national economy, in order to contribute decisively to the progress and well-being of the entire Portuguese society.
The IT staff at Lusitania had modernized its infrastructure and used Veeam to back up its VMware environment, but needed to add to that as the company’s data and backup needs grew. “We wanted to expand our Veeam solution and we also needed to back up more Oracle databases and file servers, but we didn’t have enough time in our backup window to add more backup jobs,” said Miguel Rodelo, senior systems engineer at Lusitania. “We decided to test new solutions, and started to request proofs of concept (POC) for different products.”
Rodelo and his enterprise IT provider, David Domingos, chief sales officer at CloudComputing.pt, had attended VMWorld 2018 in Barcelona, where they stopped by the ExaGrid booth at the conference to learn more about the tiered backup storage solution, and ended up requesting a POC. “We decided together to bet on the ExaGrid technology,” said Rodelo. “I said that if the technology is as good as it claims to be I will buy it, and my reseller said that if it was that good, he would tell every client in Portugal about it.
“ExaGrid was the last POC that we were analyzing, and it ended up being the fastest and easiest to implement, and compared to the other products we were looking into at the same time, it was clear that ExaGrid offered the best backup performance, especially when it came to our Oracle data. I expected ExaGrid to integrate well with Veeam, and it did, but when I saw that I can also use Oracle RMAN to make direct backups to ExaGrid, I decided to implement ExaGrid as our central data storage for backups,” said Rodelo.
After working with ExaGrid to deliver high-performance backup storage to his client at Lusitania, David Domingos is eager to recommend the tiered backup storage solution to more CloudComputing.pt clients. “One of the best features of the ExaGrid system is that the client doesn’t feel the impact of data deduplication because of the Landing Zone feature. When you look at traditional storage, you run into capacity issues, but ExaGrid’s deduplication resolves those issues. In addition, ExaGrid speaks all of the languages of the backup apps and software, so if a client is using multiple approaches, such as Veeam and Oracle RMAN, or even Commvault or Veritas, ExaGrid will support all of them. ExaGrid is versatile and that adds to the value it brings our clients.”
ExaGrid writes backups directly to a disk-cache Landing Zone, avoiding inline processing and ensuring the highest possible backup performance, which results in the shortest backup window. Adaptive Deduplication performs deduplication and replication in parallel with backups so that an RTO and RPO can be easily met. Available system cycles are utilized to perform deduplication and offsite replication for an optimal recovery point at the disaster recovery site. Once complete, the onsite data is protected and immediately available in its full undeduplicated form for fast restores, VM Instant Recoveries, and tape copies while the offsite data is ready for disaster recovery.
Read the complete Success Story to learn more about Rodelo’s experience using ExaGrid. ExaGrid’s published customer success stories and enterprise stories demonstrate how satisfied customers are with ExaGrid’s unique architectural approach, differentiated product, and unrivaled customer support.
About CloudComputing.pt
CloudComputing.pt was founded in 2010 with the objective to provide services to the corporate market based on Cloud Computing, Mobility and Information Security. The motivation to work in these fields is based on the strategic view that the organization's efficiency is measured by the capacity to share business information in real time with the right people in a safe manner anywhere. This way we promote clients' continuous innovation and value, based on the following skills: UEM Security, Identity and Access Management, Cloud and On-Premise Security and Infrastructure.
About ExaGrid
ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. Visit us at exagrid.com or connect with us on LinkedIn . See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our customer success stories .
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005277/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
